New Products In Brief

The latest product approvals and launches in cardiology, orthopedics, diagnostics and more.

Cook Medical Inc.’s Zenith fenestrated endovascular graft for abdominal aortic aneurysm repair gained PMA supplement approval April 4. Featuring a bare suprarenal stent at the proximal end of the graft containing 10 or 12 barbs for additional proximal fixation to resist migration, the implant is designed to treat abdominal aortic aneurysms in patients who are anatomically unsuitable for treatment with currently approved AAA endovascular grafts due to a short infra-renal neck. Cook is seeking a Medicare new-technology add-on payment for the Zenith fenestrated graft for 2013. During a Feb. 14 CMS “town hall” meeting, Tara Mastracci, a vascular surgeon at the Cleveland Clinic and a consultant for Cook, said that the endovascular stent graft offers substantial clinical benefit as a repair option for patients with short infra-renal necks who would not have undergone surgery to treat AAA because of severe co-morbidities. (See Also see "Cook Medical Makes Its Case For Medicare New-Tech Add-On Payments" - Medtech Insight, 20 February, 2012..) It will launch later this year.

Cook’s Zenith fenestrated AAA graft is designed to treat abdominal aortic aneurysms in patients who are anatomically unsuitable for treatment...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Medtech M&A Resurges: How To Define Startup Exit Strategy

 

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.

Intuitive Surgical Sees Early Wins With Da Vinci 5, Lifts FY25 Guidance As Tariff Impact Eases

 
• By 

For the full year, the company now expects tariffs to increase the cost of sales by approximately 1% of revenue, plus or minus 20 basis points. This is lower than the previous estimate of approximately 1.7% of revenue. The updated gross margin guidance for 2025 is 66%-67%, up from 65%-66.5%.

ForSight Sets Its Sights On Automating Delicate Eye Procedures

 
• By 

ForSight Robotics is developing a robotic platform to automate cataract and other eye surgeries, aiming to ease surgeon strain and expand access. Backed by $200m in total funding, it's targeting a first human surgery using Oryom by year-end and is in discussions with US FDA.